Brought to you by 
Kos terminates Advicor agreement with Bristol-Myers Squibb
04 Feb 2002
Executive Summary
DuPont Pharmaceuticals and Kos Pharmaceuticals (cardiovascular and respiratory therapeutics) have agreed to collaborate on developing cardiovascular drugs for the US and Canadian markets, beginning with Kos's Phase III cholesterol-lowering product Nicostatin.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kos terminates Advicor agreement with Bristol-Myers Squibb
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice